Acccording (sic) to a commentary on a Cochrane review of the efficacy of ω-3 and ω-6 polyunsaturated fatty acids (PUFAs) in patients with attention deficit hyperactivity disorder (ADHD), only “low-certainty evidence” supports the notion that such supplementation is more effective than placebo for alleviating ADHD symptoms. In addition, “high-certainty evidence” indicates that PUFA supplementation does not improve core ADHD symptoms, according to the commentary authors.